Key result
Streptozotocin-induced diabetes in HuB/LPL1 mice caused severe hyperlipidemia and increased atherosclerosis, but did not alter lipid profiles or atherosclerosis in HuB or HuB/LPL1/CETP mice.
Why the study?
Does streptozotocin-induced diabetes alter lipoprotein profiles and atherosclerosis in genetically modified mice expressing human apolipoprotein B?
Does streptozotocin-induced diabetes alter lipoprotein profiles and atherosclerosis in genetically modified mice expressing human apolipoprotein B?
In a mouse model expressing human apoB, the combination of heterozygous lipoprotein lipase deletion and streptozotocin-induced diabetes leads to severe hyperlipidemia and increased atherosclerosis.
No change to clinical lipid management in diabetes; leaves open LPL-CETP interactions in human atherosclerosis.
Both hyperglycemia and hyperlipidemia have been postulated to increase atherosclerosis in patients with diabetes mellitus. To study the effects of diabetes on lipoprotein profiles and atherosclerosis in a rodent model, we crossed mice that express human apolipoprotein B (HuB), mice that have a heterozygous deletion of lipoprotein lipase (LPL1), and transgenic mice expressing human cholesteryl ester transfer protein (CETP). Lipoprotein profiles due to each genetic modification were assessed while mice were consuming a Western type diet. Fast-protein liquid chromatography analysis of plasma samples showed that HuB/LPL1 mice had increased VLDL triglyceride, and HuB/LPL1/CETP mice had decreased HDL and increased VLDL and IDL/LDL. All strains of mice were made diabetic using streptozotocin (STZ); diabetes did not alter lipid profiles or atherosclerosis in HuB or HuB/LPL1/CETP mice. In contrast, STZ-treated HuB/LPL1 mice were more diabetic, severely hyperlipidemic due to increased cholesterol and triglyceride in VLDL and IDL/LDL, and had more atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Kako et al. (2002) studied Atherosclerosis and hyperlipidemia in diabetes. Streptozotocin (STZ) vs. Different genetic strains was evaluated on Lipoprotein profiles and atherosclerosis. Streptozotocin-induced diabetes in HuB/LPL1 mice caused severe hyperlipidemia and increased atherosclerosis, but did not alter lipid profiles or atherosclerosis in HuB or HuB/LPL1/CETP mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: